News Releases

Year

23 Nov '21

Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 23, 2021-- Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch , chief executive officer, co-founder, and chair, will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx Conference taking place virtually on Tuesday,

PDF Version

11 Nov '21

Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021

Evidence supports P. gingivalis as a driver of Alzheimer’s in easily identified patient population Successful identification of target population and therapeutic dose inform next steps SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 11, 2021-- Cortexyme, Inc.

PDF Version

04 Nov '21

Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 4, 2021-- Cortexyme, Inc. (Nasdaq: CRTX) announced that it will participate at the 14 th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program on Thursday, November 11,

PDF Version

26 Oct '21

Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression

In overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline Clinical data validated upstream mechanism of action

PDF Version

27 Sep '21

Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 27, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal Phase 2/3 trial in Alzheimer’s disease and a growing pipeline of therapeutics for degenerative diseases, today announced that it will participate at the upcoming 14 th

PDF Version

08 Sep '21

Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588

First participants dosed in clinical trial of second-generation gingipain inhibitor differentiated by novel compound properties and anticipated once daily administration Clinical advancement of pipeline delivers on commitment to bring innovation to an increasing range of P.

PDF Version

07 Sep '21

Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 7, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer's disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, announced that Casey Lynch ,

PDF Version

25 Aug '21

Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit

GAIN Trial analysis of anti-P. gingivalis antibodies in cerebrospinal fluid supports upstream role of pathogenic bacterium in key Alzheimer’s pathologies SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 25, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s

PDF Version

18 Aug '21

Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 18, 2021-- Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, will participate as a featured

PDF Version

09 Aug '21

Cortexyme Provides Business Update and Reports Second Quarter 2021 Results

GAIN Trial top-line data for disease modification in Alzheimer’s expected by mid-November 2021 Phase 2 REPAIR sub-study results evaluating periodontal disease expected by mid-November 2021 Current cash position sufficient to fund operations through 2023 SOUTH SAN FRANCISCO, Calif.

PDF Version

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 27